Clinical efficacy of Nafamostat Mesylate in combination with Favipiravir for COVID-19 pneumonia treatment review article

Alleviation and treatment of the extensive detrimental implications of COVID-19 have materialised into the primary objectives of scientists and virologists along with pathologists assigned with the responsibility of provisioning of care for infected patients. Development and introduction of vaccines have been, till to date, primarily at the prototypical phase. The significance of utilisation of combined drug therapies has been considered to be paramount from the perspective of application of clinical information collected from previous viral epidemics. One prospective treatment application has involved the Multi Drug Therapy (MDT) based approach with utilisation of the combination of drugs Nafamostat Mesylate and Favipiravir with the purpose of reduction of the infectious intensity of COVID-19 viral strain. On account of the extensive prevalence of patients becoming infected with the Novel Coronavirus strain, MDT procedures have been mostly favoured by scientists and clinical virologists with the explicit objective of determination of the probability of such combined drug therapies in terms of assisting the recovery of COVID-19 infected patients. The previous researches conducted on the procedural particulars of treatments regarding effective antidote development for COVID-19 infected patients had brought forth various clinical outcomes on such innovative treatment initiatives concerning the observed effects of MDTs on such patients. The corresponding research literature review endeavour has been oriented towards collecting information regarding 2 specifically utilised medicinal substances (the previously mentioned Nafamostat Mesylate and Favipiravir drugs) for treatment purposes of COVID-19 infected individuals. Such drugs generally are associated with pharmaceutical categories such as antivirals, immune modulators, antibiotics and anticoagulants. These compounds have been utilised in a direct manner by hospital inpatients and such occurrences have permitted the researchers to examine the implications of such drugs on health conditions of COVID-19 patients in laboratory conditions as well. The corresponding study has been responsible for considering the clinical research findings of the combination of such drugs through comparison of observed outcomes.